Crossmark

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Crossref DOI link: https://doi.org/10.1186/s13005-025-00494-w

Published Online: 2025-03-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Haseeb, Mohamed E.

Mohammed, Hazem E. https://orcid.org/0000-0003-0347-8694
Yaser, Hatem

Hanen, George

Nasser, Mohamed

Yaser, Shehab

Bady, Zeyad
Funding

Funding for this research was provided by:

Assiut University
License Information

Text and Data Mining valid from 2025-03-26

Version of Record valid from 2025-03-26
More Information

Article History

Received: 31 August 2024

Accepted: 24 February 2025

First Online: 26 March 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below